Many people with tuberculosis (TB) in South Africa are never diagnosed or are diagnosed only once their symptoms have become quite severe. One solution to diagnosing more people more quickly is the expanded use of new digital X-ray technology. Now, an independent assessment of digital X-ray pilot projects in six districts in South Africa sheds light on how well this intervention works in the real world. Tiyese Jeranji reports.
Tuberculosis (TB) disease and all the disruption and stress that goes along with it can take a toll on someone’s mental health, and mental health problems can in turn make someone more vulnerable to TB. In the wake of World Mental Health Day 2022, Tiyese Jeranji explores the complex links between mental health and TB.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.
Cryptococcal meningitis is the second biggest killer of people living with HIV after tuberculosis (TB). Now, a global initiative, the Ending Cryptococcal Meningitis Deaths by 2030 Strategic Framework aims to get the gold standard drug to treat cryptococcal meningitis – flucytosine – registered in countries that need it. Amy Green reports.
Developing COVID-19 vaccines in less than a year came from repurposing multiple, decade-old vaccine research platforms, but too many lives were lost, and a new goal of developing vaccines in 100 days is needed to counter the next global pathogen, experts say.
Over 150 000 people who had TB in South Africa in 2018 were not diagnosed, according to findings from South Africa’s long-awaited National Tuberculosis Prevalence Survey. One reason for this is that an unexpectedly high number of people do not show the typical TB symptoms and are never x-rayed. Amy Green reports.
In allowing section 21 applications as part of a controlled compassionate access programme, SAHPRA has essentially shifted the responsibility for deciding whether the anti-parasitic ivermectin is safe and effective enough to be used in the treatment of COVID-19 to doctors. This places an enormous responsibility on doctors, writes Adele Baleta.
While likely millions of people in South Africa have latent tuberculosis (TB) infection, only between three and 10% of these people ever fall ill with TB. Cutting-edge research conducted in South Africa has now taken us a significant step closer to a test that can predict who will and who will not fall ill with TB. Such a test, if simple and affordable, could potentially revolutionise TB prevention efforts.
South Africa is set to produce its first vaccine in 25 years, but it won’t be a COVID-19 jab. Plans are however in place to “fill and finish” COVID-19 vaccines in South Africa. Laura Lopez Gonzalez has the details.
The U=U campaign is based on a simple message – an undetectable viral load in people living with HIV equals an untransmissible virus. The U=U campaign, argues Mandisa Dukashe, has the power to motivate people living with HIV to adhere to ARVs, achieve viral suppression, and subsequently lead long and healthy lives while preventing HIV transmission to sexual partners and their babies.
Before any COVID-19 vaccines can be made available in South Africa, they must be authorised by South Africa’s medicines regulator—the South African Health Products Regulatory Authority (SAHPRA). Catherine Tomlinson explores how SAHPRA is preparing to review and authorise the use of COVID-19 vaccines in the country and the different authorisation approaches they may use.
The recent budget policy statement shows South Africa finds itself in a very tight fiscal space where it has to navigate a global pandemic along with other health challenges such as rising rates of non-communicable diseases. Russell Rensburg argues that the Health Promotion Levy should be increased to 20% – which will raise much-needed revenue that will contribute to preventing disease and reducing healthcare costs.
